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We examined overall and specific cancer risks among Swedish subjects who had been hospitalised one or more times for psoriasis.
A database was created by identifying such patients from the Swedish Hospital Discharge Register and linking them with the Cancer
Registry. Follow-up of patients was carried out from the last hospitalisation through 2004. A total of 15 858 patients were hospitalised
for psoriasis during 1965–2004, of whom 1408 developed cancer, giving an overall standardised incidence ratios (SIRs) of 1.33.
A significant excess was noted for squamous cell skin cancer, and for cancers of the upper aerodigestive tract, oesophagus, stomach,
liver, pancreas, lung, kidney and bladder as well as non-Hodgkin lymphoma. Many of these may reflect the effects of alcohol drinking
and tobacco smoking. Patients with multiple hospitalisations showed high risk, particularly for oesophageal (SIR 6.97) and skin
(SIR 4.76) cancers.
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Psoriasis is a chronic disorder that affects the skin and joints
variying from minor localised patches to complete body coverage
(Ritchlin, 2007). Its prevalence in Western populations is
estimated to be around 2–3% (Gudjonsson and Elder, 2007).
The cause of psoriasis is poorly understood, but is believed to
include a genetic component (Brandrup et al, 1982; Duffy et al,
1993; Krueger and Ellis, 2005); concordance in monozygotic twins
is about 70%, whereas in dizygotic twins this is only 20% (Krueger
and Ellis, 2005). Psoriasis is an immune-mediated disorder, for
which T cells are abnormally activated to release cytokines, which
cause inflammation and rapid production of skin cells (Griffiths
and Voorhees, 1996). It is not clear what factors trigger the
activation of T cells. Stress, excessive alcohol consumption and
smoking can aggravate psoriasis (Kimball et al, 2005). The choice
among many potential treatment options depends upon the type of
psoriasis, its location and severity (Boehncke et al, 2006).
Normally, medications with the least adverse reactions are
preferred, and those with significant toxicity are used only for
severe unresponsive disease. The treatment ladder (Lebwohl, 2005)
includes topical treatments (medicated ointments or creams, the
first step), phototherapy (ultraviolet (UV) radiation, including oral
psoralen and UVA, psoralen and ultraviolet A radiation (PUVA),
the second step), and systemic treatment (including immuno-
suppressive drugs, methotrexate and cyclosporine, the third step).
An increased risk of cancer has been predicted among psoriasis
patients because of the dysregulated immune function and the
potential carcinogenicity of certain therapeutic regimens, such as
UV exposure and immunosuppressant drugs (Arellano, 1997;
IARC, 2000). An increased risk of skin cancer has been reported in
most studies (Frentz and Olsen, 1999; Hannuksela-Svahn et al,
2000; Boffetta et al, 2001). However, for cancers in other sites,
evidence is still limited because of the small numbers of patients
involved and short follow-up times. We have carried out here a
longitudinal cohort study to quantify the subsequent cancer risk in
hospitalised psoriasis patients, using the Swedish nationwide
registers; it is by far the largest to date, covering 15858 patients
and allowing a separate analysis of patients with multiple
hospitalisations and thus with severe psoriasis.
PATIENTS AND METHODS
We used the Swedish Hospital Discharge Register, founded in
1964–1965 by the National Board of Health and Welfare with a
complete national wide coverage since 1987, to create a cohort of
psoriasis patients. A total of 15858 patients were retrieved from
the registry according to the seventh (1964–1968, code 706), eighth
(1969–1986, code 696), ninth (1987–1996 code 696) and tenth ICD
code (1997, code L40). This cohort was linked to the national
Swedish Cancer Registry, founded in 1958 with close to 100%
coverage, to ascertain all incident cancers from the start of
follow-up through 2004. The Cancer Registry used a four-digit
code according to ICD-7 to identify tumours during the study
period. Additional linkages were carried out to national census
data to obtain individual occupational status, national Registry of
Causes of Death to identify date of death,and the Emigration
Registry to identify date of emigration. All linkages were carried
out by the use of an individual national identification number that
is assigned to each person in Sweden for their lifetime; it was
replaced by a serial number for each person to provide anonymity.
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hospitalisation for psoriasis until diagnosis of cancer, death,
emigration or closing date (31 December 2004), whichever came
first. The follow-up time was divided into three periods: 1–4, 5–9
and X10 years. Standardised incidence ratios (SIRs) were
calculated as the ratio of observed to expected numbers of cases.
Expected numbers were calculated using the incidence rates for
all individuals without a history of psoriasis, and the rates were
standardised by 5-year age, gender, period (5 years group),
socioeconomic status and residential area (Esteve et al, 1994).
For cancers of the female reproductive system, rates were also
standardized for age at first childbirth and parity. The 95%
confidence interval of the SIR was calculated assuming a Poisson
distribution, and they were rounded to the nearest two decimals
(Esteve et al, 1994). All analyses were carried out using the SAS
statistical package (version 9.1; SAS Institute, Cary, NC, USA). The
ethics committee at Karolinska Institute, Stockholm, Sweden,
approved this study.
RESULTS
Among the 15858 patients hospitalised in Sweden for psoriasis
during 1965–2004 9251 patients (58. 3%) were hospitalised only
once, 2689 (16.9%) twice, 1255 (7.9%) three times, 1663 (16.8%)
for more than three times. The follow-up time ranged from 0 to 40
years, with a median follow-up of 10 years. Only those cancers,
which developed 1 year after last hospitalisation were calculated
and a total of 1408 patients developed subsequent cancer after
being hospitalised for psoriasis, giving an overall SIR of 1.33 (all
1þ), as shown in Table 1. For specific cancer sites, only those
cancer sites with at least 15 cases during the whole follow-up
period were listed. The highest SIR of 2.97 was noted for
oesophageal cancer. The risk for squamous cell skin cancer was
significantly increased during the whole follow-up period, but for
melanoma no increase was noted. The risks of cancers of the upper
aerodigestive tract, stomach, liver, pancreas, lung, kidney, bladder,
and nervous system and non-Hodgkin lymphoma were also
significantly increased. The risk for some cancers, such as
pancreatic cancer (5.63) and non-Hodgkin lymphoma (3.93), was
very high during the (excluded) first year, probably because of a
concomitant diagnosis. We further calculated the risks among
male and female patients separately (data not shown). The risk of
cancers in the upper aerodigestive tract, lung, kidney and bladder
was somewhat higher among female patients, whereas the risk of
live cancer was higher among male patients.
Multiple hospitalisations may reflect the disease severity, and we
examined cancer risk among psoriasis patients by the number of
hospitalisations (Table 2). The overall SIR was 1.25 for psoriasis
patients who have been hospitalised once, and it was increased to
1.40 for those with 2–3 hospitalisations and to 1.61 for those with
more than three hospitalisations. The SIR was higher for almost all
the cancer sites when psoriasis patients had multiple hospitalisa-
tions, with an exception for upper aerodigestive tract and stomach
cancers. We tested for the significance of the trend in the number
of hospitalisations. Oesophageal and squamous cell skin cancers
showed an increasing trend with the number of hospitalisations.
To study effects in relation to the changing therapeutic regimens
and diagnosis criteria, we analysed cancer risk among psoriasis
patients who were hospitalised in the 1970s, 1980s and 1990s (data
not shown). The overall SIR was marginally higher among patients
hospitalised in the 1990s compared with those hospitalised earlier.
For specific cancer sites, the risk did not change during the study
periods. We tested for the significance of the temporal trends,
which was increased only for stomach cancer.
DISCUSSION
In this population-based study of 15858 psoriasis patients
identified from the Swedish Hospital Discharge Register, a 33%
excess incidence of overall cancers was noted, largely attributable
Table 1 Standardised incidence ratios (SIRs) for subsequent cancer in patients with hospitalised psoriasis by follow-up time
Follow-up interval (years)
1–4 5–9 X10 All 1+
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 15 2.38 1.33 3.93 12 1.91 0.98 3.35 21 1.79 1.11 2.74 48 1.97 1.46 2.62
Oesophagus 10 4.30 2.05 7.94 6 2.52 0.91 5.52 12 2.54 1.31 4.45 28 2.97 1.97 4.30
Stomach 16 1.62 0.92 2.64 10 1.07 0.51 1.98 26 1.57 1.02 2.30 52 1.45 1.08 1.91
Colon 22 1.11 0.69 1.68 27 1.34 0.88 1.95 33 0.83 0.57 1.16 82 1.03 0.82 1.27
Rectum 13 1.16 0.61 1.98 17 1.49 0.87 2.40 24 1.05 0.67 1.56 54 1.18 0.89 1.55
Liver 15 1.94 1.08 3.21 13 1.71 0.91 2.93 29 2.08 1.39 2.99 57 1.95 1.47 2.52
Pancreas 15 2.00 1.12 3.31 6 0.82 0.29 1.80 20 1.49 0.91 2.30 41 1.45 1.04 1.97
Lung 42 1.99 1.43 2.69 37 1.73 1.22 2.38 71 1.71 1.33 2.15 150 1.78 1.51 2.09
Breast 35 1.02 0.71 1.42 42 1.22 0.88 1.65 85 1.15 0.91 1.42 162 1.13 0.97 1.32
Cervix 4 1.11 0.29 2.87 4 1.15 0.30 2.97 11 1.63 0.81 2.93 19 1.38 0.83 2.15
Endometrium 12 1.56 0.80 2.73 10 1.30 0.62 2.41 8 0.53 0.23 1.05 30 0.98 0.66 1.41
Ovary 8 1.27 0.54 2.52 5 0.82 0.26 1.93 8 0.68 0.29 1.35 21 0.87 0.54 1.33
Prostate 44 1.12 0.82 1.51 38 0.92 0.65 1.27 96 1.03 0.84 1.26 178 1.03 0.88 1.19
Kidney 18 2.27 1.34 3.59 9 1.16 0.53 2.21 18 1.25 0.74 1.99 45 1.50 1.09 2.00
Urinary bladder 20 1.52 0.93 2.36 18 1.35 0.80 2.13 43 1.58 1.14 2.13 81 1.51 1.20 1.88
Melanoma 9 1.05 0.47 2.00 5 0.56 0.18 1.32 21 1.09 0.67 1.67 35 0.95 0.66 1.32
Skin, squamous cell 26 2.56 1.67 3.76 25 2.35 1.52 3.47 40 1.74 1.24 2.37 91 2.08 1.67 2.55
Nervous system 7 0.89 0.35 1.84 8 1.03 0.44 2.03 29 1.90 1.27 2.73 44 1.42 1.03 1.91
Endocrine glands 4 0.83 0.22 2.16 7 1.46 0.58 3.02 16 1.71 0.98 2.78 27 1.42 0.94 2.08
Non-Hodgkin lymphoma 27 2.44 1.61 3.55 9 0.79 0.36 1.51 24 1.03 0.66 1.54 60 1.31 1.00 1.69
Leukemia 9 1.91 0.86 3.63 10 2.15 1.02 3.96 8 0.89 0.38 1.77 27 1.47 0.97 2.14
All 401 1.54 1.39 1.70 333 1.26 1.13 1.41 674 1.26 1.17 1.36 1408 1.33 1.26 1.40
Bold type, 95% confidence interval (CI) does not include 1.00; underline type, 99% CI does not include 1.00.
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stomach and liver and to non-Hodgkin lymphoma. This study has
the advantage that it includes individual data on an entire
population. The additional strengths include its prospective design
and completeness of follow-up of psoriasis and cancer patients. All
the data came from nation-wide databases guaranteeing reliable
information. One limitation is that because of multiple compar-
isons some findings may be due to chance, while another is the
lack of information on treatment and on possible confounding
factors, such as alcohol drinking and tobacco smoking. Moreover,
our data will not directly applicable to all patients with psoriasis as
hospitalised patients must represent a severe subgroup.
The increase in overall cancer incidence is consistent with a few
earlier studies from the Nordic countries (Frentz and Olsen, 1999;
Hannuksela-Svahn et al, 2000), and also one from Sweden using
patients hospitalised before 1983 (Boffetta et al, 2001), somewhat
overlapping with our study population. Possible mechanisms for
the increase of cancer risk could be immunological, that is, general
tendency to cell proliferation beyond the epidermis (Boffetta et al,
2001) or carcinogenic effect of treatments, especially for the
increase of squamous cell skin cancer and non-Hodgkin
lymphoma, both of them are related to immunological deficiency.
However, other factors, such as smoking and alcohol drinking are
important. The highest risks were noted during the first year after
last hospitalisation for psoriasis, which could be due to lead-time
bias because of concomitant diagnosis.
For specific cancers, the increased risk of squamous cell skin
cancer has been noted by many earlier studies (Chuang et al, 1992;
Hannuksela et al, 1996; McKenna et al, 1996; Frentz and Olsen,
1999; Hannuksela-Svahn et al, 2000; Boffetta et al, 2001). The
increase is thought to be due to UV exposure, but it may be
increased by concomitant treatments. The risk for melanoma was
close to unity. The risk for non-Hodgkin lymphoma was margin-
ally increased, though confined to less than 5 years after
hospitalisation. As this malignancy can be a sign of dysregulated
immunity, it may be relevant to the evidence that severe psoriasis
patients may receive immunosuppressive drugs. For nervous
system tumours and leukaemia, the increase was confined to
specific follow-up periods and chance cannot be excluded.
As alcohol drinking and tobacco smoking are often reported to
be associated with psoriasis (Poikolainen et al, 1990; Naldi et al,
1992; Schafer, 2006; Favato, 2008), including one Swedish study
(Lindegard, 1986), the increase in cancers of the upper aero-
digestive tract, oesophagus, stomach, liver, pancreas, lung, kidney
and bladder could reflect these factors. Unfortunately, information
about individual drinking and smoking habits was lacking in this
study, precluding an examination. The magnitude of alcohol and/
or smoking effects on psoriasis has been evaluated in many earlier
studies, but the data were heterogeneous because most of them
were limited by small sample sizes (Schafer, 2006). In a recent
population-based study involved 5687 hospitalised psoriasis
patients in Finland (Poikolainen et al, 1999), where the health
care system and diagnosed criteria were similar to Sweden, the
mortality for alcohol and smoking-related causes was significantly
increased among these patients compared with general population,
with a standardised mortality ratio of 2.14 (men) and 1.47
(women) for alcohol-related causes and 1.44 (men) and 1.61
(women) for smoking-related causes, respectively. For these
alcohol and smoking-related cancer sites, the risks were somewhat
higher in female patients, with an exception of liver cancer,
suggesting that stress could be related to the association between
psoriasis and smoking and alcohol consumption.
We examined the data according to the number of hospital
visits, using this as a surrogate for disease severity and chronicity.
The overall cancer risk was associated with the number of
hospitalisation. The excess in oesophagus, pancreas, lung and
squamous cell skin cancers were most pronounced for patients
with multiple hospitalisations. The highest risk of 6.97 was noted
for oesophageal cancer among patients hospitalised more than
three times. Multiple hospitalisations witness about the severity of
Table 2 Standardised incidence ratios (SIRs) for subsequent cancer in psoriasis patients by number of hospitalisations
Number of hospitalisations
1 2-3 X4
Trend test
Cancer site O SIR O SIRs O SIRs P-value
Upper aerodigestive tract 33 2.18 9 1.51 6 1.85 0.49
Oesophagus 6 1.03 13 5.59 9 6.97 0.01
Stomach 33 1.48 13 1.50 6 1.23 0.75
Colon 54 1.08 18 0.92 10 0.96 0.53
Rectum 35 1.23 12 1.08 7 1.18 0.88
Liver 33 1.81 17 2.38 7 1.81 0.72
Pancreas 21 1.19 7 1.02 13 3.52 0.06
Lung 92 1.75 37 1.79 21 1.89 0.78
Breast 104 1.10 41 1.23 17 1.13 0.66
Cervix 11 1.18 6 1.89 2 1.50 0.52
Endometrium 21 1.05 7 0.98 2 0.59 0.50
Ovary 11 0.69 6 1.07 4 1.59 0.12
Prostate 105 1.00 49 1.14 24 0.97 0.85
Kidney 28 1.48 10 1.38 7 1.81 0.76
Urinary bladder 51 1.54 16 1.21 14 1.93 0.74
Melanoma 24 1.00 8 0.92 3 0.73 0.62
Skin, squmous cell 34 1.26 29 2.67 28 4.76 0.01
Nervous system 29 1.44 8 1.10 7 2.01 0.68
Endocrine glands 16 1.30 6 1.35 5 2.31 0.31
Non-Hodgkin lymphoma 35 1.22 15 1.36 10 1.72 0.31
Leukaemia 15 1.29 9 2.04 3 1.32 0.60
All 835 1.25 358 1.40 215 1.61 0.01
Bold type, 95% confidence interval (CI) does not include 1.00; underline type, 99% CI does not include 1.00.
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oesophageal, skin and pancreatic cancers should be an extra
concern, which may be indications for medical surveillance.
The diagnostic criteria and treatment for psoriasis patients have
changed during the follow-up period, and we examined the
temporal trends of cancer development among these patients. For
most specific cancers, the risk did not change during the study
periods. Topical corticosteroids are the most commonly prescribed
treatments for psoriasis in the world (Lebwohl, 2003). Topical tars
were ever used as an essential component of the Goeckerman
regimen, but the use of tars has decreased greatly because of its
staining on the skin. Phototherapy is a standard treatment for
patients with moderate-to-severe psoriasis who have not re-
sponded to topical therapies (Lebwohl, 2003). Psoralen and
ultraviolet A radiation (PUVA) was developed in the 1970s and
has been used by some 13% of the Swedish psoriatics in the 1990s
(Zachariae et al, 2001). Methotrexate has also been used for many
years in the treatment of psoriasis, but its use was limited because
of hepatotoxicity (Lebwohl, 2003). Cyclosporin alleviates psoriasis
by inhibiting the immune system, which has been used for the
treatment of psoriasis for more than a decade ago (Lebwohl, 2003).
However, its long-term use is associated with nephrotoxicity and it
has been limited to a maximum use of 1 year recently, thus its
carcinogenetic effect could be largely excluded. In view of the
various medications used in psoriasis treatment during the follow-
up periods, the relatively constant risks observed throughout the
study period suggest that, besides the therapeutic effect, psoriasis
itself, with the contribution by smoking and alcohol drinking, may
be associated with an increased cancer risk.
A 33% excess incidence of cancer was noted among psoriasis
patients, involving squamous cell skin cancer and cancers related
to alcohol drinking and tobacco smoking.
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